Abstract Objective: The purpose of this study was to assess the efficacy and safety of Chinese herbal medicine (CHM) in the treatment of chronic heart failure (CHF) patients according to syndrome differentiation. Methods: In this multicenter, randomized, double-blind, placebo-controlled clinical trial, a total of 220 CHF patients were assigned to receive CHM or placebo granules without decoction according to syndrome differentiation in addition to their standard western treatment for 4 weeks. The change in the left ventricular ejection fraction (LVEF) was the primary outcome, and the changes in the TCM syndrome scores (TCM-SS) and New York Heart Association functional classification (NYHA-FC) were the secondary outcomes.
Introduction
Heart failure (HF) can be defined as an abnormality of cardiac structure or function leading to the failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues despite normal filling pressures (or only at the expense of increased filling pressures). 1 In addition, according to the nature of the clinical presentation, HF is divided into acute and chronic HF. 1 Despite major improvements in the treatment of virtually all cardiac disorders, heart failure (HF) is an exception because its prevalence is rising and only small prolongations in survival have been achieved. 2 The diagnosis and treatment of cardiovascular disease (CVD) have developed rapidly in the past several decades. The mortality of many CVDs, with the exception of HF, has decreased. The annual hospital discharge of subjects with a primary diagnosis of HF has increased steadily since 1975, and the discharge rate now exceeds 1 million per year, although it may be leveling off in the United States. 3, 4 In 2003, a random sample survey of 15,518 urban or rural residents between 35 and 74 years of age in China indicated that the prevalence rate of heart failure was 0.9%. According to the result, there were approximately 4,000,000 HF subjects in China. 5 Another retrospective investigation of 10,714 HF subjects in the full-year segments of 1980, 1990, and 2000 was conducted in 42 hospitals in China, and this study revealed that the underlying cause of HF in 45.6% of HF subjects was coronary heart disease (CHD). 6 The mortality of CHD has been reduced due to the wide application of percutaneous coronary intervention and coronary artery bypass grafting. The early mortality in subjects with acute myocardial infarction may have declined by 75% during the past half-century; 7 however, the survivors still have CHD and remain at risk for subsequent episodes of ischemic myocardial damage with further loss of myocardium and possibly HF.
The western medicine (WM) treatment for HF is standardized around the world. 8, 9 The conventional therapeutic approaches in HF management are angiotensin-converting enzyme inhibitors (ACEI), b-adrenergic blockers, and diuretics. In China, the integrative treatment of western and traditional Chinese medicine for HF is usually applied and has been developed as a treatment model. 8 CHM has been used in China for thousands of years. Syndrome differentiation and treatment variation are the basic principles of TCM in the understanding and treatment of diseases. Syndrome differentiation is the comprehensive analysis of the clinical information gained by the four main diagnostic TCM procedures, namely, observation, listening, questioning, and pulse analysis, and it is used to guide the choice of treatment by CHM. We would like to test the hypothesis that it is efficacious and safe for patients to take CHM granules according to syndrome differentiation.
In this study, a multicenter, randomized, double-blind, placebo-controlled trial was conducted. The aim was to evaluate the efficacy and safety of CHM on CHF according to syndrome differentiation.
Materials and methods

Study design
This multicenter, randomized, double-blind, placebocontrolled study was conducted in seven centers of four provinces in China from May 2010 to September 2012 and was reported in accordance with the 2010 CORSORT statements. 10 The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of Dongfang Hospital affiliated to Beijing University of Chinese Medicine (No. 201002102). All of the subjects voluntarily signed an informed consent form before enrollment.
Sample size estimation
The sample size calculation was calculated with the following formula:
The estimated number of subjects in each group was 98.18012, and 196.36024 subjects are needed to have two groups. The number was increased to 215.18012 assuming a maximum dropout rate of less than or equal to 10%, and a total of 220 subjects were included (110 subjects in each group).
Participants Diagnostic criteria
Diagnostic criteria of CHF: 2007 China Guideline for the Diagnosis and Treatment of CHF.
8
Heart function standard: The Criteria for Diagnosis and Treatment of Heart Disease first published by the New York Heart Association (NYHA). 
Inclusion criteria
The primary heart disease is CHD (with diagnosis for CHD confirmed by coronary angiography, coronary computed tomography, history of acute myocardial infarction, limb-salvage Q wave for electrocardiogram (ECG), ECG test, radionuclide examination support, etc.). The included patients also had no history of hypertension or of taking antihypertensive drugs and exhibited a blood pressure under 160/100 mmHg. With a history of CHD, the following symptoms and signs were observed: difficulty breathing, fatigue, fluid retention (edema), left ventricular enlargement, end systolic volume of left ventricular increase and LVEF 40, and NYHA functional classification II or III. Male or female subjects between 40 and 75 years old; If there was a "No" answer for any issue, the subject could not enter into this research.
Exclusion criteria
Patients with one of the following diseases were excluded: 1) serious valvular heart disease; 2) pericardial disease; 3) cardiomyopathy; 4) congenital heart disease; 5) acute myocardial infarction (AMI) within four weeks; 6) cardiac shock; 7) acute myocarditis or serious arrhythmia with variation in hemodynamics. Patients who suffer from pulmonary artery hypertension caused by cor pulmonale, pulmonary embolism, or stroke within a half year were also excluded. (Table 1) . A total of 220 subjects were included in this study.
Intervention
According to the 2007 China Guidelines for the Diagnosis and Treatment of Chronic Heart Failure, 8 all patients in the two groups received the standardized western medicine treatment, which includes angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs), b-blockers and diuretics. The subjects were treated with CHM or placebo granules twice per day for four weeks according to syndrome differentiation. The study focuses mainly on the following four syndromes: qi deficiency, blood stasis, water retention and yang deficiency. The CHM drugs and placebo were prepared and provided by Beijing Kangren Tang Pharmaceutical Co., Ltd. (Beijing, China). In the CHM group, there were prescriptions for four syndromes (qi deficiency, blood stasis, water retention and yang deficiency), and the placebo was prepared with the same appearance, smell and weight as the treatment administered to the CHM group. The CHM drugs and placebo were numbered according to a random number table that was blinded to both the doctors and patients. The patients were administered with CHM or placebo according to their syndromes at the beginning and two weeks later. The patients were prohibited from taking other Chinese medicines during the treatment period. The granule quality met the internal control standards of Beijing Kangren Tang Pharmaceutical Co., Ltd. (Beijing, China) and complied with GMP (Good Manufacturing Practice) standards.
The drugs for the treatment of hypertension (HBP), diabetes mellitus, dyslipidemia and other diseases could be used reasonably. In addition, the reason, name, and dosage should be recorded in detail.
Outcome measurements
The study was designed to evaluate the therapeutic efficacy and safety of CHM treatment for CHF over a period of four weeks. The primary endpoint was LVEF. The second outcomes were the NYHA functional classification and the TCM syndrome scores. The outcome measures were evaluated after two and four weeks of treatment. The level of LVEF was detected using the modified Simpson's rule. Standardized training and conformance testing were administered to all investigators before the study. Each syndrome differentiation and TCM syndrome score was evaluated by three physicians, and the results required agreement from at least two physicians. A total of 65 clinical symptoms or signs were evaluated as TCM symptoms, and these were defined as TCM syndrome scores. The standard of TCM symptoms are scored as without (0), very light (1), light (2), medium (3), heavy (4), or very heavy (5).
The rate of disappearance of symptoms or signs found for the CHF patients were evaluated after two and four weeks of treatment.
Safety evaluations were carried out before and after the study, and these included general physical examinations, routine blood, hepatic and renal function examinations, and electrocardiogram. In addition, any adverse events were reported and recorded in case report form (CRF).
Randomization and blinding
The random number table, drug codes and allocation scheme of the groups were produced using the SAS statistical software by the Center for Drug Clinical Pharmacology Research of Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine. The work associated with compiling the blind number was completed by statistical analysis personnel of Dongzhimen Hospital. This study took two times to reveal the blind result. The data were locked after the blinding review, at which point it was time to reveal the grouping results (A and B groups). The blind grouping results were then provided to the medical statisticians. The blinding information of CHM or placebo was revealed on the clinical summary meeting after the statistical analysis.
Data analysis and statistics
The statistical analysis was performed using the Statistical Package for the Social Sciences 16.0 (SPSS 16.0). The data were entered twice into an EpiData database (Version 3.1) by two independent data entry operators. The two databases were compared for consistency, and all inconsistencies were resolved by referring to the original data collection CRF. In addition, the blinding results were revealed twice. After the results were first revealed, the statistical analysis of the differences between groups A and B were initiated. After all of the statistical analyses were finished, we revealed which group the CHM group was.
The data were analyzed based on the Intention-To-Treat (ITT) and the per-protocol set (PPS) for adherence. The results of the data analysis presented in this manuscript were mainly based on ITT. The measurement data are expressed as the means AE standard deviation. The data for the two groups was tested using a normal test and a homogeneity of variance test. The results are expressed as 95% confidence intervals (CIs). The Chi-square test or Wilcoxon rank-sum test for categorical variables was used to assess the comparability of the groups at baseline. The differences in the characteristics of the subjects of the two groups at baseline were compared by independent sample t-test, and nonparametric statistics with the ManneWhitney U test were used for the comparisons between groups, such as the course of disease and LVEF.
We described the changes in the LVEF and TCM syndrome scores. The changes in the scores were compared between the baseline and after two and four weeks of treatment using paired t-tests to measure the effectiveness. Two-way analysis of variance for repeated measures (ANOVA) was used to compare the effects of two groups, and Wilcoxon tests were used to compare the changes in categorical measures. The level of significance was set to 0.05, i.e., there were significant differences if P < 0.05. All of the tests were two-tailed.
The safety evaluation included all of the randomized patients. The adverse event rates were compared between the two groups with the Chi-square test or Fisher's exact test (if the expected value for any count was less than 5).
Results
Participants and numbers analyzed
A total of 220 patients were recruited and randomly assigned. There were 110 patients in the CHM group and 110 in the placebo group (Fig. 1, according to CONSORT 2010) .
One patient in the placebo group was excluded for failing to meet the inclusion criteria. During the treatment period, 4 patients in the CHM group and 1 patient in the placebo group were lost to follow-up because of poor compliance, etc., and 1 patient in the placebo group dropped out due to an adverse event.
The clinical characteristics of the CHF patients are shown in Table 2 . The mean AE SD ages of the patients in the CHM and placebo groups were 66.04 AE 7.24 and 66.96 AE 7.46 years (P Z 0.33). There was no significant difference in any of the baseline clinical variables between the two groups (Pgt >0.05).
Primary outcome
The levels of LVEF after two and 4 weeks of treatment were significantly higher than those at baseline in both groups (within-group: P < 0.001 for all, Table 3 ). After 4 weeks of treatment, the level of LVEF in the CHM group was increased by 13.1 compared with the baseline level (between-group: P < 0.001, Table 3 and Fig. 2 ). In addition, there was a significant time course effect of CHM versus placebo in the LVEF (repeated-measures ANOVA, P < 0.001, Fig. 2 ). After 2 weeks of treatment, the level of LVEF in the CHM group was increased by 9.26 compared with the baseline level (between-group: P < 0.001, Table 3 and Fig. 2 ).
Secondary outcomes
The TCM syndrome scores after 2 and 4 weeks of treatment were significantly lower than the baseline scores in both groups (within-group: P < 0.001 for all, Table 3 ). After 2 weeks of treatment, the TCM syndrome scores in the CHM group were decreased by 23.5 compared with the baseline (between-group: P < 0.001, Table 3 and Fig. 3 ). After four weeks of treatment, the TCM syndrome scores in the CHM group were decreased by 34.2 compared with the baseline (between-group: P < 0.001, Table 3 and Fig. 3 ). In addition, there was a significant time course effect of CHM versus placebo in the TCM syndrome scores (repeated-measures ANOVA, P < 0.001, Fig. 3 ).
In the CHM group, the distention of the jugular vein (P Z 0.021), expectoration (P Z 0.044), abdominal distention (P Z 0.004), and rib pain (P Z 0.005) were significantly less than that observed in the placebo group after 2 weeks of treatment ( Table 4 ). The symptoms of fatigue (P Z 0.001), less gas and lazy words (P Z 0.001), dizziness (P Z 0.003), gasping for breath (P Z 0.027), abdominal distention (P Z 0.011), nausea (P Z 0.001) and emesis (P Z 0.012) were significantly less in the CHM group compared with the placebo group after treatment for four weeks (Table 4) .
After 2 weeks of treatment, there was no significant difference in the change in the NYHA functional classification between the two groups (P Z 0.064, Table 3 and Fig. 4 ), whereas after four weeks of treatment, there was significant difference between the two groups (P < 0.001, Table 3 and Fig. 5 ).
Adverse events
A total of 110 patients in the CHM group and 109 patients in the placebo group were included in safety analysis (Table 5 ). There was no obvious change in the safety evaluations of the 219 patients before and after treatment.
The total number of adverse events was two in the CHM group and three in the placebo group (P Z 0.683), and one patient experienced a serious adverse event in each group. One male patient in the placebo group died because of acute heart failure induced by mood swing despite positive rescue. One female patient in the CHM group suffered from palpitations, and the electrocardiogram results indicated atrial fibrillation (heart rate: 121 bmp), which was treated with an intravenous drip of deslanoside injection, resulting in an immediate return to normal. Other than these patients, there was no report of any serious adverse events (SAEs) in both groups.
Discussion
We performed a multicenter, double-blinded, randomized controlled study to confirm the efficacy and safety of CHM for the treatment of CHF according to syndrome differentiation. Compared to the placebo, CHM was more effective in improving the LVEF, TCM syndrome scores and NYHA functional classification when combined with standardized western medicine. We used a placebo with the same weight and packaging as the CHM granules to achieve double blindness for the CHF patients and researchers during the study.
CHM has been widely used for the treatment of CHF, and some studies have confirmed its efficacy. 16e21 In the literature, qi deficiency (5731 cases, 16.40%), blood stasis (6377 cases, 18.25%), water retention (3445 cases, 9.86%) and yang deficiency (6489 cases, 18.57%) are the common syndrome differentiations of CHF patients. 22 We performed an epidemiological investigation of the syndrome differentiation of CHF patients caused by CHD in 14 hospitals in China. The investigation results indicated that qi deficiency (497 cases, 28.56%), blood stasis (448 cases, 25.75%), water retention (186 cases, 10.69%) and yang deficiency (142 cases, 8.16%) are the main syndrome differentiations of CHF patients. 22 Therefore, we selected these four syndrome differentiations as the main differentiations in this study. The drugs used in this study are common and have been used for the treatment of CHF for a long time. Although the previous studies treated patients with stationary capsules or granules, 18, 19 we gave our patients drugs according to their syndrome differentiation. This study shows the efficacy of CHM for the treatment of CHF according to syndrome differentiation. LVEF is not an index of contractility because it depends on volumes, preload, afterload, heart rate, and valvular function and is not the same as the stroke volume. 1 Similarly to previous studies, 18, 19 CHM treatment according to syndrome differentiation improved the LVEF of CHF patients after two and four weeks of treatment. After two and four weeks, the LVEF of the CHM group was higher than that of the placebo group. The LVEF level of CHF patients could be improved by treatment with the Qiliqiangxin capsule for 12 weeks. 20 Compared with the Qiliqiangxin capsule, the efficacy found in this study was significant after two weeks of treatment because the baseline level of LVEF in this study was higher than that obtained with the Qiliqiangxin capsule.
Repeated-measures ANOVA showed significant time course effects of CHM versus placebo in the LVEF. A characteristic of this study is that the LVEF levels of the CHF patients included were not higher than 40%. Therefore, the findings could reveal the effect of CHM on CHF patients with depressed LVEF. CHM treatment according to syndrome differentiation may influence the long time prognosis because LVEF is directly related to long-term prognosis. 23 The symptoms are a reflection of the TCM syndrome. The TCM syndrome score is a semi-quantitative evaluation method used to assess symptoms and has been used in the efficacy evaluation in TCM clinical practice. 24, 25 Compared The data are shown as the mean differences AESE. ** P < 0.001 for the difference between the baseline and the result after two or four weeks of treatment (within-group difference). ## P < 0.001 for the difference between the baseline and the result after two or four weeks of treatment (between CHM and placebo group difference). ff P < 0.001: time course effect of CHM versus placebo by repeated-measures ANOVA. Repeated-measures ANOVA indicated significant time course effects of CHM versus placebo in LVEF (P < 0.001). Figure 3 Variation in TCM syndrome scores over time. The data are shown as the mean differences AESE. ** P < 0.001 for the difference between the baseline and the result after two or four weeks of treatment (within-group difference). ## P < 0.001 for the difference between the baseline and the result after two or four weeks of treatment (between CHM and placebo group difference). ff P < 0.001: time course effect of CHM versus placebo by repeated-measures ANOVA. Repeatedmeasures ANOVA indicated significant time course effects of CHM versus placebo in TCM syndrome scores (P < 0.001).
with other studies, 18, 19 we did not use the classifications of "notable effective", "effective", and "ineffective" as the evaluation criterion. Similarly to other studies, 17e19 this study found that CHM treatment can improve the TCM syndrome scores of CHF patients. After two weeks of treatment, the TCM syndrome scores of the CHF patients in the CHM group decreased to levels lower than those observed in the placebo group. Significant differences between the two groups could be observed during the treatment period. We also found that the CHM treatment can markedly relieve the symptoms and signs of CHF patients. This effect was observed after two and four weeks of treatment, which means that the effect of CHM on different symptoms or signs may be observed at different times.
In this study, the NYHA functional classification of all CHF patients was NYHA II or NYHA III. After two weeks of treatment, there was no difference in the NYHA functional classification between the two groups. After four weeks of treatment, the variation in the NYHA functional classification in the CHM group was better than that obtained in the placebo group. The Qiliqiangxin capsule influences NYHA functional classification after eight weeks of treatment 20 because there were some patients with NYHA IV at baseline. This finding means that the efficacy of CHM on the NYHA functional classification requires a long treatment time. However, caution should be taken in interpreting the NYHA functional classification results. Although there was no difference in the NYHA functional classification at baseline, there were more CHF patients with NYHA Ⅱ in the CHM group than in the placebo group. Further study is needed to validate this finding. With respect to safety, one patient in the placebo group died, and one patient in the CHM group experienced atrial fibrillation. There was no direct relationship between these serious adverse events and intervention. In addition, there were no differences in the AEs or SAEs between the two groups. In total, the incidence of SAEs was low; therefore, CHM treatment according to syndrome differentiation appeared to be safe and well tolerated.
Compared with other studies, 18, 19 this study only included CHF patients whose disease was caused by CHD. Therefore, it cannot reflect the effect of CHM treatment according to syndrome differentiation on CHF caused by other heart diseases. In this study, we did not follow-up with the patients for a long time after the treatment; thus, it is difficult to draw a conclusion regarding the incidence of cardiovascular events due to CHM in CHF patients and the long-term prognosis. In addition, we did not measure the N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) before and after treatment. The level of NT-pro-BNP is associated with mortality and morbidity in HF patients. 26, 27 Therefore, a long-term follow-up randomized, placebocontrolled study is necessary in the future to evaluate the effect of CHM treatment according to syndrome differentiation on CHF caused by different heart diseases.
Conclusion
This study found that CHM treatment according to syndrome differentiation could improve the LVEF, the TCM syndrome scores, the disappearance of symptoms or signs and the NYHA functional classification of CHF patients. CHM treatment according to syndrome differentiation appeared to be a safe and effective treatment for CHF as an assistant treatment. Figure 4 The variation of NYHA functional classification of 2 weeks. Figure 5 The variation of NYHA functional classification of 4 weeks. ## P < 0.001. 
